Burkitt Lymphoma Treatment Market Overview 2020, Emerging Technology Trends, Global Industry Size, Growth, Share, Business Insight, Challenges, Opportunities, Regional Statistics

SEATTLE, March 25, 2021, (PHARMIWEB) — Global Burkitt Lymphoma Treatment Market

Burkitt lymphoma is a cancer of the lymphatic system, which develops from B lymphocytes and is characterized by rapid, abnormal growth of these lymphocytes. The condition usually leads to lymph node enlargement in various parts of the body, including spleen, liver, bone marrow, and the central nervous system. Burkitt lymphoma is a type of high-grade non-Hodgkin lymphoma (NHL). The World Health Organization has classified Burkitt lymphoma as an endemic that affects children in Africa aged 4-7 years, sporadic that occurs globally, and immunodeficiency-associated type that affects people suffering from HIV/AIDS. According to a survey carried out by the Cancer Therapy Advisor, Burkitt lymphoma accounts for up to 30% of the global pediatric lymphomas and less than 1% of lymphoma cases in adults, especially with a weakened immune system. Several cellular therapies, such as T-cell therapy and CAR T-cell therapy, are currently being developed, which can use the patient’s own T-cells to attack the non-Hodgkin’s lymphoma cells.

Request for the trending sample of this report: https://www.coherentmarketinsights.com/insight/request-sample/1547

Global Burkitt Lymphoma Treatment Market Dynamics

Rising incidence of HIV is expected to augment the growth of the global Burkitt lymphoma treatment market, as Burkitt lymphoma is an AIDS-defining cancer expected to occur more frequently in people suffering from HIV. According to the Burkitt Lymphoma Society, the condition accounts for around 40% of the childhood non-Hodgkin lymphoma cases globally. It also accounts for as many as 40% of all non-Hodgkin lymphomas in HIV/AIDS patients. According to the Cancer Therapy Advisor, Burkitt lymphoma is the most common pediatric cancer with the disease incidence being 2-3 times higher in sub-Saharan Africa, with an estimated incidence of 3–6 cases per 100,000 children per year. The disease is termed as endemic Burkitt lymphoma, where a majority of cases are related to Epstein-Barr virus (EBV).

Moreover, various government and non-government organizations are undertaking research initiatives to launch efficient treatments and create awareness about the rare disease. For instance, the National Cancer Institute initiated the Burkitt Lymphoma Genome Sequencing Project (BLGSP) to explore potential genetic changes in patients suffering from Burkitt lymphoma (BL) that could lead to better prevention, detection, and treatment of this rare and aggressive cancer. Moreover, researchers at Forgarty International Center and National Cancer Institute are working together to address global health needs related to various cancer types, including Burkitt lymphoma. Non-profit organization such as Burkitt Lymphoma Society supports and connects patients and caregivers by connecting the patients who have received efficient care for Burkitt lymphoma, thus providing information and creating awareness about the rare medical condition. Also, in 2017, the Lymphoma Research Foundation granted US$ 700,000 to funding innovative research that serves education programs, outreach initiatives, and patient services, thus accelerating the global Burkitt lymphoma treatment market expansion.

Exclusive offer!!! Purchase the report at a discounted rate!!!

Apply Promo Code “CMIFIRST1000” and Get Up to 30% Discount

Quick Buy – Burkitt Lymphoma Treatment Market Research Report: https://bit.ly/31idsp6

The presence of potential therapies for the prevention of Burkitt lymphoma is expected to augment the market growth over the forecast period. For instance, Viracta Therapeutics, Inc., initiated Phase 1 b/2 trial for Tractinostat in combination with Valganciclovir indicated for Epstein-Barr virus-positive (EBV+) lymphomas. According to the Cancer Research UK, 2015, around 200,000 new cases and over 140,000 deaths are estimated to be recorded each year due to EBV-associated cancers. Also, the National Cancer Institute initiated Phase 1 clinical trials for antibody therapy, directed against CD19- blinatumomab, a recombinant bispecific antibody in combination with Lenalidomide with Relapsed or Refractory Non-Hodgkin’s Lymphoma (NHL).

Moreover, the FDA approved a radioimmunotherapy, named Zevalin (Ibritumomab tiuxetan), in combination with a radioactive substance linked to a monoclonal antibody, named rituximab, to treat patients suffering from certain types of non-Hodgkin lymphoma, including Burkitt lymphoma.

Global Burkitt Lymphoma Treatment Market – Regional Analysis

North America is expected to hold a dominant position in the global Burkitt lymphoma treatment market over the forecast period, owing to rising prevalence of lymphoma over the forecast period. According to the survey conducted by WebMD, LLC, in 2015, around 1,200 people are diagnosed each year in the U.S., of which around 59% are aged 40 years and above. Moreover, Burkitt lymphoma shows a higher prevalence among HIV-infected patients.

The Burkitt lymphoma treatment market in Europe is expected to witness high growth, owing to increasing prevalence of sporadic form of Burkitt lymphoma in the U.K. According to the survey by Lymphoma Action Organization, 2015, around 210 people are affected by Burkitt lymphoma every year in the U.K.

To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/burkitt-lymphoma-treatment-market-1547

Competitive Analysis

The key players participating in the global Burkitt lymphoma treatment market are Novartis AG, Sanofi Pasteur, Eisai Inc., Cellerant Therapeutics, Inc., Pfizer, Inc., Merck KGaA, Seattle Genetics, Inc., Karyopharm Therapeutics, Inc., Boehringer Ingelheim GmbH, and AbbVie Inc. these companies offer various effective products to cater to the rising unmet needs of patients suffering from relapsed or refractory Burkitt lymphoma. For instance, Servier, in collaboration with Pfizer Inc., initiated the Phase 1 study in 2015 for gene-edited allogeneic CAR19 T-cells (UCART19) to treat relapsed/ refractory acute lymphoblastic leukemia (ALL) in pediatric patients.

Market Taxonomy

On the basis of therapy type:

• Chemotherapy
• Targeted Therapy
• Radioimmunotherapy

On the basis of route of administration:

• Oral
• Intravenous

On the basis of disease type:

• Endemic
• Sporadic
• Immunodeficiency-associated

By end-user:

• Hospitals
• Clinics
• Ambulatory Surgical Centers

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837